Transient Immunomodulation Allows Repeated Injections of AAV1 and Correction of Muscular Dystrophy in Multiple Muscles
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Abstract
Exon-skipping AAV1-U7-associated therapy is a promising treatment for Duchenne muscular dystrophy (DMD). We have shown earlier that the newly rescued dystrophin protein is stably expressed for months in mice and dogs, and does not induce immune rejection of transduced fibers. In this study, we used the dystrophic mdx mouse as a preclinical model to characterize the immune response to the adeno-associated virus 1 (AAV1) vector, and tested the feasibility of administering multiple AAV1 injections to extend the treatment to several muscles. We found that re-injections of AAV1 vector are compromised as early as 3 days after the first injection, coincident with a rapid increase in AAV1-specific immunoglobulin M (IgM) and IgG in the serum. Adoptive transfer of immune sera confirmed the rapid appearance of an AAV1 neutralization activity, and experiments with immunoglobulin-deficient (microKO) mice proved that antibodies (Abs) are the only effectors responsible for AAV1-U7 elimination. It is important to note, however, that the AAV2 vector still generated an adverse immune response in microKO mice. By blocking the T-B crosstalk with anti-CD40 Abs and CTLA4/Fc fusion protein, we found that a mere 5 days of immunomodulation treatment was sufficient to totally abrogate the formation of anti-AAV1 Abs and to allow for the correction of muscular dystrophy in multiple muscles, provided the treatment was administered during each challenge.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multiple studies showed CD28/B7 and CD40/CD40L blockade resulted in mitigation of inflammatory response and allowed for vector re-administration [203–205].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [204]
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Kitamura, D., Roes, J., Kühn, R., & Rajewsky, K. (1991) · Nature · doi:10.1038/350423a0 · Cited by 1,783
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Recombinant adeno-associated virus for muscle directed gene therapy
Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., Pathak, R., Raper, S. E., & Wilson, J. M. (1997) · Nature Medicine · doi:10.1038/nm0397-306 · Cited by 654
Boumpas, D. T., Furie, R., Manzi, S., Illei, G. G., Wallace, D. J., Balow, J. E., Vaishnaw, A., & on behalf of the BG9588 Lupus Nephritis Trial Group (2003) · Arthritis & Rheumatism · doi:10.1002/art.10856 · Cited by 618
Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart
Wang, Z., Zhu, T., Qiao, C., Zhou, L., Wang, B., Zhang, J., Chen, C., Li, J., & Xiao, X. (2005) · Nature Biotechnology · doi:10.1038/nbt1073 · Cited by 608
Gene therapy vectors based on adeno-associated virus type 1
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson, J. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3994-4003.1999 · Cited by 541
Directed evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538
Rescue of Dystrophic Muscle Through U7 snRNA-Mediated Exon Skipping
Goyenvalle, A., Vulin, A., Fougerousse, F., Leturcq, F., Kaplan, J.-C., Garcia, L., & Danos, O. (2004) · Science · doi:10.1126/science.1104297 · Cited by 506
Self-citationRutledge, E. A., Halbert, C. L., & Russell, D. W. (1998) · Journal of Virology · doi:10.1128/jvi.72.1.309-319.1998 · Cited by 452
Acharyya, S., Villalta, S. A., Bakkar, N., Bupha-Intr, T., Janssen, P. M. L., Carathers, M., Li, Z.-W., Beg, A. A., Ghosh, S., Sahenk, Z., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30556 · Cited by 438
Chao, H., Liu, Y., Rabinowitz, J., Li, C., Samulski, R. J., & Walsh, C. E. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0219 · Cited by 366
Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV)
Erles, K., Seb�kov�, P., & Schlehofer, J. R. (1999) · Journal of Medical Virology · doi:10.1002/(sici)1096-9071(199911)59:3<406::aid-jmv22>3.0.co;2-n · Cited by 342
rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice
Gregorevic, P., Allen, J. M., Minami, E., Blankinship, M. J., Haraguchi, M., Meuse, L., Finn, E., Adams, M. E., Froehner, S. C., Murry, C. E., et al. (2006) · Nature Medicine · doi:10.1038/nm1439 · Cited by 307
Somatic reversion/suppression of the mouse mdx phenotype in vivo
Hoffman, E. P., Morgan, J. E., Watkins, S. C., & Partridge, T. A. (1990) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(90)90195-s · Cited by 277
Rivera, V. M., Gao, G.-P., Grant, R. L., Schnell, M. A., Zoltick, P. W., Rozamus, L. W., Clackson, T., & Wilson, J. M. (2005) · Blood · doi:10.1182/blood-2004-06-2501 · Cited by 276
Scallan, C. D., Jiang, H., Liu, T., Patarroyo-White, S., Sommer, J. M., Zhou, S., Couto, L. B., & Pierce, G. F. (2006) · Blood · doi:10.1182/blood-2005-08-3229 · Cited by 271
Genetic Fate of Recombinant Adeno-Associated Virus Vector Genomes in Muscle
Schnepp, B. C., Clark, K. R., Klemanski, D. L., Pacak, C. A., & Johnson, P. R. (2003) · Journal of Virology · doi:10.1128/jvi.77.6.3495-3504.2003 · Cited by 262
Immune Responses to Adeno-Associated Virus Vectors
Zaiss, A., & Muruve, D. (2005) · Current Gene Therapy · doi:10.2174/1566523054065039 · Cited by 213
Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid
Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R. A., Chen, C. S., Johnston, J., et al. (2006) · Nature Medicine · doi:10.1038/nm1445 · Cited by 208
Hybrid Vectors Based on Adeno-Associated Virus Serotypes 2 and 5 for Muscle-Directed Gene Transfer
Hildinger, M., Auricchio, A., Gao, G., Wang, L., Chirmule, N., & Wilson, J. M. (2001) · Journal of Virology · doi:10.1128/jvi.75.13.6199-6203.2001 · Cited by 207
Halbert, C. L., Standaert, T. A., Aitken, M. L., Alexander, I. E., Russell, D. W., & Miller, A. D. (1997) · Journal of Virology · doi:10.1128/jvi.71.8.5932-5941.1997 · Cited by 205
Halbert, C. L., Standaert, T. A., Wilson, C. B., & Miller, A. D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9795-9805.1998 · Cited by 203
Rivière, C., Danos, O., & Douar, A. M. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302766 · Cited by 192
Self-citationTreatment of human disease by adeno-associated viral gene transfer
Warrington, K. H., & Herzog, R. W. (2006) · Human Genetics · doi:10.1007/s00439-006-0165-6 · Cited by 155
Davis, J. C., Totoritis, M. C., Rosenberg, J., Sklenar, T. A., & Wofsy, D. (2001) · PubMed · Cited by 146
Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model
Denti, M. A., Rosa, A., D’Antona, G., Sthandier, O., Angelis, F. G. D., Nicoletti, C., Allocca, M., Pansarasa, O., Parente, V., Musarò, A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508917103 · Cited by 142
Manning, W. C., Zhou, S., Bland, M. P., Escobedo, J. A., & Dwarki, V. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.4-477 · Cited by 140
Combinatorial engineering of a gene therapy vector: directed evolution of adeno‐associated virus
Perabo, L., Endell, J., King, S., Lux, K., Goldnau, D., Hallek, M., & Büning, H. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.849 · Cited by 136
Wang, Z., Allen, J. M., Riddell, S. R., Gregorevic, P., Storb, R. F., Tapscott, S. J., Chamberlain, J. S., & Kuhr, C. S. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.093 · Cited by 132
Characterization of Tissue Tropism Determinants of Adeno-Associated Virus Type 1
Hauck, B., & Xiao, W. (2003) · Journal of Virology · doi:10.1128/jvi.77.4.2768-2774.2003 · Cited by 124
Sarukhan, A., Camugli, S., Gjata, B., von Boehmer, H., Danos, O., & Jooss, K. U. (2001) · Journal of Virology · doi:10.1128/jvi.75.1.269-277.2001 · Cited by 122
Self-citationWang, Z., Allen, J. M., Riddell, S. R., Gregorevic, P., Storb, R. F., Tapscott, S. J., Chamberlain, J. S., & Kuhr, C. S. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.ft-273 · Cited by 106
Identification of mouse AAV capsid-specific CD8+ T cell epitopes
Sabatino, D. E., Mingozzi, F., Hui, D. J., Chen, H., Colosi, P., Ertl, H. C. J., & High, K. A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.009 · Cited by 96
McCullough, K. C., Crowther, J. R., Butcher, R. N., Carpenter, W. C., Brocchi, E., Capucci, L., & Simone, F. (1986) · PubMed · Cited by 92
Determination of Specific CD4 and CD8 T Cell Epitopes after AAV2- and AAV8-hF.IX Gene Therapy
Chen, J., Wu, Q., Yang, P., Hsu, H.-C., & Mountz, J. D. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.10.006 · Cited by 76
CTLA4Ig: a novel inhibitor of costimulation
Dall’Era, M., & Davis, J. C. (2004) · Lupus · doi:10.1191/0961203303lu1029oa · Cited by 69
Miao, C. H., Ye, P., Thompson, A. R., Rawlings, D. J., & Ochs, H. D. (2006) · Blood · doi:10.1182/blood-2005-11-4532 · Cited by 53
Blaha, P., Bigenzahn, S., Koporc, Z., Sykes, M., Muehlbacher, F., & Wekerle, T. (2005) · Transplantation · doi:10.1097/01.tp.0000164510.25625.70 · Cited by 47
Noninvasive monitoring of therapeutic gene transfer in animal models of muscular dystrophies
Bartoli, M., Poupiot, J., Goyenvalle, A., Perez, N., García, L., Danos, O., & Richard, I. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302594 · Cited by 39
Self-citationThe “rescue” of dystrophin synthesis in boys with Duchenne muscular dystrophy
Nicholson, L. V. B. (1993) · Neuromuscular Disorders · doi:10.1016/0960-8966(93)90109-w · Cited by 31
Gonin, P., Arandel, L., van Wittenberghe, L., Marais, T., Perez, N., & Danos, O. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.716 · Cited by 30
Self-citationGenetic and structural determinants of virus neutralizing antibodies
Crowe, J. E., Suara, R. O., Brock, S. C., Kallewaard, N. L., House, F. S., & Weitkamp, J.-H. (2001) · Immunologic Research · doi:10.1385/ir:23:2-3:135 · Cited by 28
T.O. 2 Rescue of dystrophin in the GRMD dog by multi-exon skipping using engineered U7 snRNAs
Vulin, A., Goyenvalle, A., Barthélémy, I., Leturcq, F., Jc, K., Chelly, J., Danos, O., Blot, S., & García, L. (2006) · Neuromuscular Disorders · doi:10.1016/j.nmd.2006.05.249 · Cited by 2
Self-citation
Cited by
Progress toward Gene Therapy for Duchenne Muscular Dystrophy
Chamberlain, J. R., & Chamberlain, J. S. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.019 · Cited by 224
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
Delivery is key: lessons learnt from developing splice‐switching antisense therapies
Godfrey, C., Desviat, L. R., Smedsrød, B. H., Piétri‐Rouxel, F., Denti, M. A., Disterer, P., Lorain, S., Nogales‐Gadea, G., Sardone, V., Anwar, R., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607199 · Cited by 166
Self-citationMuscle Function Recovery in Golden Retriever Muscular Dystrophy After AAV1-U7 Exon Skipping
Vulin, A., Barthélémy, I., Goyenvalle, A., Thibaud, J. L., Beley, C., Griffith, G., Benchaouir, R., Hir, M. L., Unterfinger, Y., Lorain, S., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.181 · Cited by 161
Self-citationHareendran, S., Balakrishnan, B., Sen, D., Kumar, S., Srivastava, A., & Jayandharan, G. R. (2013) · Reviews in Medical Virology · doi:10.1002/rmv.1762 · Cited by 113
Metadata
- Authors
- Lorain, S., Gross, D.-A., Goyenvalle, A., Danos, O., Davoust, J., & Garcia, L.
- Affiliations
- Inserm (FR)
- Hôpital Necker-Enfants Malades (FR)
- University of Oxford (GB)
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2008-03
- Volume
- 16
- Issue
- 3
- Pages
- 541-547
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2005245653
- Cited by
- 62
- References
- 46
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 3 · 2023: 2 · 2022: 6 · 2021: 2 · 2020: 3 · 2019: 2 · 2018: 3 · 2017: 8 · 2016: 2 · 2015: 3 · 2014: 5 · 2013: 7 · 2012: 4
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 3142 d)
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Centre National de la Recherche Scientifique
- Duchenne Parent Project
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- Duchenne muscular dystrophy, AAV1, exon skipping, mdx mice, adoptive transfer, AAV2, immunomodulation, gene therapy
- MeSH terms
- Abatacept, Dependovirus, Animals, Antibody Formation, Fluorescent Antibody Technique, Genetic Vectors, Immunoglobulin G, Immunoglobulin M, Immunoglobulins, Mice, Inbred C57BL, Transduction, Genetic, Genetic Therapy, Immunoconjugates, CD40 Antigens, Muscular Dystrophy, Duchenne, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.